Taxotere® (docetaxel) – New warning

- On October 5, 2018, the FDA approved an update to the *Warnings and Precautions* section of the Taxotere (docetaxel) drug label regarding the risk of enterocolitis and neutropenic colitis.

- Taxotere is generically available and is an antineoplastic agent indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck.

- Enterocolitis and neutropenic colitis (typhlitis) have occurred in patients treated with Taxotere alone and in combination with other chemotherapeutic agents, despite the coadministration of granulocyte-colony stimulating factor.

    — Caution is recommended for patients with neutropenia, particularly at risk for developing gastrointestinal complications. Enterocolitis and neutropenic enterocolitis may develop at any time, and could lead to death as early as the first day of symptom onset.
    — Patients should be closely monitored from onset of any symptoms of gastrointestinal toxicity.
    — Patients should be informed to contact their healthcare provider with new or worsening symptoms of gastrointestinal toxicity.

- Taxotere carries boxed warnings for toxic deaths, hepatotoxicity, neutropenia, hypersensitivity reactions, and fluid retention.